Shionogi & Co Ltd (SGIOF) 40.4452 $SGIOF
Klebsiella Pneumoniae Infections Pipeline Review 2015 - 18 Companies & 34 Drug Profiles
M2 - Fri Jul 10, 2:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kbn3w/klebsiella) has announced the addition of the "Klebsiella Pneumoniae Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Arsanis Biosciences GmbH - Cellceutix Corporation - Debiopharm International S.A. - Melinta Therapeutics, Inc - Merck & Co., Inc. - Northern Antibiotics Oy - Nosopharm SAS - Novan, Inc. - Pfizer Inc. - Phico Therapeutics Ltd. - Sarepta Therapeutics, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - Theraclone Sciences, Inc. - Trana Discovery, Inc. Drug Profiles - Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - BXN-112 - CB-027 - CB-618 - CC-1807 - CTIX-1278 - Debio-1454 - dusquetide - IBN-1 - Klebsiella pneumoniae vaccine - Monoclonal Antibodies for Klebsiella Pneumoniae Infections - Monoclonal Antibody for Klebsiella Pneumoniae Infections - MVX-506 - NAB-7061 - NAB-739 - NAB-741 - NOSO-95300 - NVN-1000 - NVN-4428 - PT-4 - RX-05 - RXP-792 - RXP-873 - S-649266 - Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections - SM-295291 - SM-369926 - Small Molecule for Gram-Negative Nosocomial Infections - Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Small Molecules to Inhibit DHFR for Infectious Diseases - TP-076 - TP-138 - TP-600 For more information visit http://www.researchandmarkets.com/research/4kbn3w/klebsiella
TTPH: 48.76 (+2.09), SRPT: 30.02 (+0.66), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57)
Acinetobacter Infections Therapeutics Pipeline Review, H1 2015 - 25 Companies & 43 Drug Profiles
M2 - Thu Jul 09, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w32xnp/acinetobacter) has announced the addition of the "Acinetobacter Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - AmpliPhi Biosciences Corporation - Aridis Pharmaceuticals LLC - AstraZeneca PLC - AvidBiotics Corp. - ConjuGon, Inc. - Emergent BioSolutions Inc. - FAB Pharma - LegoChem Biosciences, Inc - Melinta Therapeutics, Inc - Microbiotix, Inc. - Northern Antibiotics Oy - Nosopharm SAS - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Phylogica Limited - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Shionogi & Co., Ltd. - Synthetic Biologics, Inc. - Techulon, Inc. - Trana Discovery, Inc. - Vaxdyn, S.L. For more information visit http://www.researchandmarkets.com/research/w3...netobacter
SYN: 3.04 (+0.19), EBS: 33.85 (+1.10), SRPT: 30.02 (+0.66), PFE: 34.36 (+0.50), AZN: 66.45 (+1.90), AKAO: 6.27 (-0.07)
Sector's Smaller Players Show The Way
EP Vantage - at Seeking Alpha - Sat Jul 04, 11:28AM CDT
With the Nasdaq biotech index proving remarkably resilient to sector-specific and macroeconomic problems alike, smart investors will continue to keep an eye out for signs of panic as a leading indicator of an overall collapse of sentiment. Nothing...
SGYP: 9.13 (+0.49), BIIB: 388.23 (-11.06), ZIOP: 11.17 (+0.69), BMRN: 141.67 (+1.54), PCYC: 261.25 (+1.70), CLDN: 1.26 (+0.01), HSP: 89.15 (+0.02), HRTX: 32.49 (+2.33), ANTH: 8.32 (+0.85), SHPG: 250.34 (+7.35), CLLS: 35.72 (+1.27), RTRX: 33.59 (+1.88), JUNO: 52.05 (+1.72), ABBV: 69.23 (+1.26), AAVL: 16.25 (+0.62), SNY: 51.49 (+2.71), PFE: 34.36 (+0.50), SLXP: 172.96 (+0.15), GSK: 42.45 (+0.65), CELG: 118.84 (+1.97), ISIS: 53.50 (+0.42), TARO: 142.57 (+1.78), PBYI: 106.25 (-2.12), NVS: 103.22 (+3.20)
Pruritus - Pipeline Review, H1 2015 - Featuring 19 Key Companies
M2 - Thu Jun 11, 9:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bppb86/pruritus) has announced the addition of the "Pruritus - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pruritus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pruritus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Amorepacific Corporation - Cara Therapeutics, Inc. - Conrig Pharma ApS - Creabilis SA - ELORAC, Inc. - FAES Farma SA - GlaxoSmithKline plc - Helsinn Holding S.A. - Hydra Biosciences, Inc. - LEO Pharma A/S - Merck & Co., Inc. - NeRRe Therapeutics Ltd - Nippon Shinyaku Co., Ltd. - RDD Pharma Ltd. - Shionogi & Co., Ltd. - Tioga Pharmaceuticals, Inc. - Trevi Therapeutics, Inc. - Vanda Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/bppb86/pruritus
VNDA: 12.41 (+0.33), MRK: 57.95 (+0.57), GSK: 42.45 (+0.65)
Global Resistant Pseudomonas Aeruginosa Infections Therapeutics Pipeline Review, H1 2015 - 11 Companies & 21 Drug Profiles
M2 - Fri Jun 05, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h6xgjr/resistant) has announced the addition of the "Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Resistant Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Resistant Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Achaogen Inc. - AstraZeneca PLC - Biolytics Pharma - CSA Biotechnologies LLC - LegoChem Biosciences, Inc - Melinta Therapeutics, Inc - Microbion Corporation - Phico Therapeutics Ltd. - Phylogica Limited - Shionogi & Co., Ltd. - Zambon Company S.p.A. Drug Profiles - ACHN-975 Prodrug - Biologic for Pseudomonas Aeruginosa Infection - Cephalosporin Beta-Lactamase Inhibitor - CSA-13 - G-10 - LCB-100200 - Monoclonal Antibodies for Gram-Negative Bacterial Infections - PT-3.33 - RXP-763 - RXP-766 - RXP-770 - RXP-792 - RXP-793 - RXP-808 - RXP-873 - S-649266 - Small Molecule for Chronic Wound Infection and Bacterial Infections - Small Molecules for Gram-Negative Bacterial Infections - Small Molecules for Multi-Drug Resistant Bacterial Infections - Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections - ZP-046 For more information visit http://www.researchandmarkets.com/research/h6xgjr/resistant
AZN: 66.45 (+1.90), AKAO: 6.27 (-0.07)
Global Hyperalgesia Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c7l5q5/hyperalgesia) has announced the addition of the "Hyperalgesia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hyperalgesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperalgesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Cara Therapeutics, Inc. - Shionogi & Co., Ltd. Drug Profiles - A-836339 - AX-007 - BAM-822 - CR-701 - GERP-001 - LASSBio-873 - Recombinant Protein to Activate IL-4 and IL-10 Receptors for Osteoarthritis and CNS - Small Molecule to Antagonize P2X3 Receptor for Central Nervous System Disorders - Small Molecules to Inhibit FLT3 for Hyperalgesia and Neuropathic Pain For more information visit http://www.researchandmarkets.com/research/c7...peralgesia
ABBV: 69.23 (+1.26)
Pruritus Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 07, 1:00PM CDT
The report "Pruritus - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Pruritus. Pruritus is a common symptom, rather than a specific disease entity, that occurs in a diverse range of skin diseases and may appear as a prominent feature of extracutaneous disorders such as systemic, neurologic, and psychiatric diseases. The incidence of pruritus increases with age and is one of the most common complaints in the elderly patient population. Most often dry skin, otherwise known as xerosis is the commonest cause in these patients. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/pruritus-pip...eport.html .
GSK: 42.45 (+0.65)
International Fenofibrate Market Status & Forecast Report 2015-2020
PRWeb - Tue Apr 07, 7:31AM CDT
The 2015 Deep Market Research Report on Global Fenofibrate Industry is a professional and in-depth study on the current state of the global Fenofibrate Market with a focus on the Chinese situation.
Sezary Syndrome Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k76vbh/sezary_syndrome) has announced the addition of the "Sezary Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. Sezary Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Sezary Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sezary Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sezary Syndrome. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Sezary Syndrome Therapeutics Clinical Trials - Eisai Co., Ltd. - Merck & Co., Inc. - Shionogi & Co., Ltd. - Kirin Holdings Company, Limited - OncoSec Medical Inc. - Janssen Global Services, LLC - Emergent BioSolutions Inc. - arGEN-X BV - Angimmune LLC For more information visit http://www.researchandmarkets.com/research/k7...y_syndrome
EBS: 33.85 (+1.10), MRK: 57.95 (+0.57), ONCS: 5.75 (-0.06)
Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation
PR Newswire - Mon Mar 30, 1:00AM CDT
Naldemedine, an investigational peripherally acting mu-opioid receptor antagonist (PAMORA) under development by Shionogi & Co., Ltd., met its primary and secondary endpoints in a phase III study (COMPOSE I) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain receiving opioid therapy. Study results showed that naldemedine (0.2 mg tablet given once daily) statistically significantly improved the frequency of spontaneous bowel movement (SBM) compared with placebo over 12 weeks. Naldemedine was generally well-tolerated with the most commonly reported side effects being gastrointestinal disorders. This is the first phase III data generated from the COMPOSE program.
Cardiac Marker Diagnostic Testing Markets 2015
M2 - Mon Feb 16, 5:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/n3jhj5/cardiac_marker) has announced the addition of the "Cardiac Marker Diagnostic Testing Markets" report to their offering. Cardiac marker diagnostic testing measures the concentration of certain proteins, i.e., biomarkers, which indicate the presence or severity of cardiovascular disease (CVD). Among the most prevalent CVDs are sudden cardiac arrest (SCA), acute myocardial infarction (AMI), congestive heart failure (CHF) and atherosclerosis. Every year, an estimated 17 million people worldwide die from a CVD. This report describes the specific market segment of the in vitro diagnostics (IVD) market devoted to cardiac marker testing, including size; growth; industry trends; product development and investment; and clinical measurement devices, reagents and supplies. Highly-attractive cardiac marker areas of growth covered in this review include: the cardiac rapid assay market, troponins, Creatine kinase-myocardial band (CK-MB) and brain natriuretic peptide (BNP) testing. Also examined are heart failure, myoglobin, homocysteine (Hcy), C-reactive protein (CRP), pulmonary embolism (PE) (D-dimer test), low-density and high-density lipoproteins (LDL and HDL), stroke, cardiac enzymes, albumin, cardiac markers used in clinical decisions, cardiac markers in renal failure, cardiac panels and point of care (POC) cardiac markers. This study also provides a thorough analysis of the companies known to be marketing, manufacturing or developing cardiac marker products in the U.S. and worldwide, as well as detailed tables, charts and figures covering the U.S., Europe and Asia markets. Key Topics Covered: 1. Overview 2. The Basics of Biomarkers 3. Cardiac Marker Testing Markets: Market Segment Analysis: Size, Growth and Share 4. Cardiovascular Disease Markers 5. Cardiac Marker Testing Development Issues 6. Business Trends in the Industry 7. Important Technology Trends 8. Company Profiles - Abbott Laboratories and SWOT Analysis - Alere and SWOT Analysis - Beckman Coulter (now part of Danaher) - Biosite, Inc. (now a brand of Alere) - bioM?rieux - CardioGenics - Chek Diagnostics - diaDexus and SWOT Analysis - Health-Chem Diagnostics (HCD) - LifeSign, LLC - Ortho-Clinical Diagnostics, Inc. and SWOT Analysis - PTS Diagnostics - PreMD, Inc. - Radiometer Medical - Randox Laboratories Ltd. - Response Biomedical - Roche Diagnostics - Sanyo Chemical Industries Ltd. - Shionogi & Co., Ltd. - Siemens Healthcare Diagnostics - Sierra Resources International - Spectral Diagnostics, Inc. For more information visit http://www.researchandmarkets.com/research/n3...iac_marker
ABT: 49.93 (+0.74), DHR: 86.65 (+0.91)
Pruritus - Pipeline Review, H2 2014
M2 - Fri Dec 19, 4:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/m2s47z/pruritus) has announced the addition of the "Pruritus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pruritus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pruritus and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pruritus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amorepacific - Cara Therapeutics - Conrig Pharma - Creabilis - ELORAC - FAES Farma - GlaxoSmithKline - Hydra Biosciences - Johnson & Johnson - LEO Pharma - Merck & Co - NeRRe Therapeutics - Nippon Shinyaku - RDD Pharma - Santen Pharmaceutical - Shionogi & Co - Toray Industries - Trevi Therapeutics - Vanda Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/m2s47z/pruritus
JNJ: 99.53 (+1.13), VNDA: 12.41 (+0.33), MRK: 57.95 (+0.57), GSK: 42.45 (+0.65)
Osteosarcoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/kjklc9/osteosarcoma) has announced the addition of the "Osteosarcoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteosarcoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Osteosarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Oncolytics Biotech Inc. - Med Discovery SA - Aileron Therapeutics, Inc. - Merrimack Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Sutro Biopharma, Inc. - Eleison Pharmaceuticals, Inc. - Apoplogic Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/kj...teosarcoma
MACK: 12.08 (+0.43), ONCY: 0.58 (+0.03), BLCM: 19.58 (+0.74), GSK: 42.45 (+0.65)
Ewing Sarcoma - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/l4jf65/ewing_sarcoma) has announced the addition of the "Ewing Sarcoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ewing Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ewing Sarcoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shionogi & Co., Ltd. - Amgen Inc. - AstraZeneca PLC - Daiichi Sankyo Company, Limited - Sigma-Tau S.p.A. - Oncolytics Biotech Inc. - Merrimack Pharmaceuticals, Inc. - Pharma Mar, S.A. - EntreChem, S.L. For more information visit http://www.researchandmarkets.com/research/l4...ing_sarcom
MACK: 12.08 (+0.43), ONCY: 0.58 (+0.03), AZN: 66.45 (+1.90), AMGN: 154.10 (+2.79)
Allergic Rhinitis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5vk6r/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 3M Drug Delivery Systems - ALK-Abello - Allergopharma Joachim Ganzer - AnaptysBio - Axikin Pharmaceuticals - BioTech - Celsus Therapeutics - ELORAC - Fountain Biopharma - GlaxoSmithKline - GlycoMar Limited - Hisamitsu Pharmaceutical - Johnson & Johnson - KAEL-GemVax - Laboratorios LETI - Ligand Pharmaceuticals - Mitsubishi Tanabe Pharma Corporation - Nektar Therapeutics - NeoPharm - Novartis - Oxagen Limited - Panmira - Protectimmun - Revance Therapeutics - Rottapharm - Shionogi & Co - Stallergenes - Sumitomo Dainippon Pharma - Trimel BioPharma - VentiRx For more information visit http://www.researchandmarkets.com/research/w5...c_rhinitis
JNJ: 99.53 (+1.13), RVNC: 30.96 (+1.15), CLTX: 0.49 (-0.02), GSK: 42.45 (+0.65), NKTR: 11.40 (+0.22), NVS: 103.22 (+3.20)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.67 (+0.04), IMGN: 14.44 (+0.25), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), ONTX: 2.51 (-0.09), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), OXGN: 1.39 (+0.07), XLRN: 30.03 (+0.20), KPTI: 25.57 (+0.24), NVS: 103.22 (+3.20)
Shionogi Inc. Enlists BuzzeoPDMA, a Cegedim Company to Support their Sample Management Compliance Programs
Business Wire - Thu Sep 04, 12:00PM CDT
BuzzeoPDMA, A Cegedim Company, today announced that Shionogi Inc. has selected BuzzeoPDMA's sample management services to help the company maintain compliance with the FDA's PDMA regulations. Shionogi Inc., the U.S.-based subsidiary of Shionogi & Co., Ltd., a leading Japanese pharmaceutical company, focuses in the therapeutic areas of pain, women's health and cardiovascular disease.
Research and Markets: Global Postmenopausal Vaginal Atrophy Drugs Market 2014-2018 with Actavis, Novo Nordisk, Pfizer & Shionogi & Co. Dominating
Business Wire - Tue Jul 15, 8:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbvk9b/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering.
Global Postmenopausal Vaginal Atrophy Drugs Market 2014-2018 with Actavis, Novo Nordisk, Pfizer & Shionogi & Co. Dominating
M2 - Tue Jul 15, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mstbv/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering. The Global PVA Drugs market can be divided into two segments: Topical Estrogen and Systemic Estrogen. To calculate the market size, the report considers the revenue generated from the sales of various drugs (creams, tablets, and rings) used in the treatment of PVA. Vaginal atrophy is defined as decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after the menopause. Up to 40 percent of postmenopausal women have symptoms of atrophic vaginitis. In PVA there are symptoms of redness, burning, itching, dryness, irritation, and dyspareunia. HRT, estrogen creams, and other topical preparations are used in the treatment of PVA. The report, the Global PVA Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PVA Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actavis plc - Novo Nordisk A/S - Pfizer Inc. - Shionogi & Co. Ltd. Other Prominent Vendors - ANI Pharmaceuticals Inc. - Bionovo Inc. - EndoCeutics Inc. - QuatRx Pharmaceutical Co. - PeP-Tonic Medical AB - Teva Pharmaceutical Industries Ltd. - Therapeutics MD Inc. - Upsher-Smith Laboratories Inc. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Competitive Analysis of Marketed Products - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Types - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/5m..._pva_drugs
NVO: 57.68 (+2.91), ANIP: 62.22 (+1.36), PFE: 34.36 (+0.50), TEVA: 61.38 (-0.75)
Klebsiella Pneumoniae Infections Pipeline Review 2015 - 18 Companies & 34 Drug Profiles
M2 - Fri Jul 10, 2:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kbn3w/klebsiella) has announced the addition of the "Klebsiella Pneumoniae Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Arsanis Biosciences GmbH - Cellceutix Corporation - Debiopharm International S.A. - Melinta Therapeutics, Inc - Merck & Co., Inc. - Northern Antibiotics Oy - Nosopharm SAS - Novan, Inc. - Pfizer Inc. - Phico Therapeutics Ltd. - Sarepta Therapeutics, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - Theraclone Sciences, Inc. - Trana Discovery, Inc. Drug Profiles - Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - BXN-112 - CB-027 - CB-618 - CC-1807 - CTIX-1278 - Debio-1454 - dusquetide - IBN-1 - Klebsiella pneumoniae vaccine - Monoclonal Antibodies for Klebsiella Pneumoniae Infections - Monoclonal Antibody for Klebsiella Pneumoniae Infections - MVX-506 - NAB-7061 - NAB-739 - NAB-741 - NOSO-95300 - NVN-1000 - NVN-4428 - PT-4 - RX-05 - RXP-792 - RXP-873 - S-649266 - Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections - SM-295291 - SM-369926 - Small Molecule for Gram-Negative Nosocomial Infections - Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Small Molecules to Inhibit DHFR for Infectious Diseases - TP-076 - TP-138 - TP-600 For more information visit http://www.researchandmarkets.com/research/4kbn3w/klebsiella
TTPH: 48.76 (+2.09), SRPT: 30.02 (+0.66), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57)
Acinetobacter Infections Therapeutics Pipeline Review, H1 2015 - 25 Companies & 43 Drug Profiles
M2 - Thu Jul 09, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w32xnp/acinetobacter) has announced the addition of the "Acinetobacter Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - AmpliPhi Biosciences Corporation - Aridis Pharmaceuticals LLC - AstraZeneca PLC - AvidBiotics Corp. - ConjuGon, Inc. - Emergent BioSolutions Inc. - FAB Pharma - LegoChem Biosciences, Inc - Melinta Therapeutics, Inc - Microbiotix, Inc. - Northern Antibiotics Oy - Nosopharm SAS - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Phylogica Limited - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Shionogi & Co., Ltd. - Synthetic Biologics, Inc. - Techulon, Inc. - Trana Discovery, Inc. - Vaxdyn, S.L. For more information visit http://www.researchandmarkets.com/research/w3...netobacter
SYN: 3.04 (+0.19), EBS: 33.85 (+1.10), SRPT: 30.02 (+0.66), PFE: 34.36 (+0.50), AZN: 66.45 (+1.90), AKAO: 6.27 (-0.07)
Sector's Smaller Players Show The Way
EP Vantage - at Seeking Alpha - Sat Jul 04, 11:28AM CDT
With the Nasdaq biotech index proving remarkably resilient to sector-specific and macroeconomic problems alike, smart investors will continue to keep an eye out for signs of panic as a leading indicator of an overall collapse of sentiment. Nothing...
SGYP: 9.13 (+0.49), BIIB: 388.23 (-11.06), ZIOP: 11.17 (+0.69), BMRN: 141.67 (+1.54), PCYC: 261.25 (+1.70), CLDN: 1.26 (+0.01), HSP: 89.15 (+0.02), HRTX: 32.49 (+2.33), ANTH: 8.32 (+0.85), SHPG: 250.34 (+7.35), CLLS: 35.72 (+1.27), RTRX: 33.59 (+1.88), JUNO: 52.05 (+1.72), ABBV: 69.23 (+1.26), AAVL: 16.25 (+0.62), SNY: 51.49 (+2.71), PFE: 34.36 (+0.50), SLXP: 172.96 (+0.15), GSK: 42.45 (+0.65), CELG: 118.84 (+1.97), ISIS: 53.50 (+0.42), TARO: 142.57 (+1.78), PBYI: 106.25 (-2.12), NVS: 103.22 (+3.20)
Pruritus - Pipeline Review, H1 2015 - Featuring 19 Key Companies
M2 - Thu Jun 11, 9:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bppb86/pruritus) has announced the addition of the "Pruritus - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pruritus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pruritus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Amorepacific Corporation - Cara Therapeutics, Inc. - Conrig Pharma ApS - Creabilis SA - ELORAC, Inc. - FAES Farma SA - GlaxoSmithKline plc - Helsinn Holding S.A. - Hydra Biosciences, Inc. - LEO Pharma A/S - Merck & Co., Inc. - NeRRe Therapeutics Ltd - Nippon Shinyaku Co., Ltd. - RDD Pharma Ltd. - Shionogi & Co., Ltd. - Tioga Pharmaceuticals, Inc. - Trevi Therapeutics, Inc. - Vanda Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/bppb86/pruritus
VNDA: 12.41 (+0.33), MRK: 57.95 (+0.57), GSK: 42.45 (+0.65)
Global Resistant Pseudomonas Aeruginosa Infections Therapeutics Pipeline Review, H1 2015 - 11 Companies & 21 Drug Profiles
M2 - Fri Jun 05, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h6xgjr/resistant) has announced the addition of the "Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Resistant Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Resistant Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Achaogen Inc. - AstraZeneca PLC - Biolytics Pharma - CSA Biotechnologies LLC - LegoChem Biosciences, Inc - Melinta Therapeutics, Inc - Microbion Corporation - Phico Therapeutics Ltd. - Phylogica Limited - Shionogi & Co., Ltd. - Zambon Company S.p.A. Drug Profiles - ACHN-975 Prodrug - Biologic for Pseudomonas Aeruginosa Infection - Cephalosporin Beta-Lactamase Inhibitor - CSA-13 - G-10 - LCB-100200 - Monoclonal Antibodies for Gram-Negative Bacterial Infections - PT-3.33 - RXP-763 - RXP-766 - RXP-770 - RXP-792 - RXP-793 - RXP-808 - RXP-873 - S-649266 - Small Molecule for Chronic Wound Infection and Bacterial Infections - Small Molecules for Gram-Negative Bacterial Infections - Small Molecules for Multi-Drug Resistant Bacterial Infections - Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections - ZP-046 For more information visit http://www.researchandmarkets.com/research/h6xgjr/resistant
AZN: 66.45 (+1.90), AKAO: 6.27 (-0.07)
Global Hyperalgesia Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c7l5q5/hyperalgesia) has announced the addition of the "Hyperalgesia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hyperalgesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperalgesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Cara Therapeutics, Inc. - Shionogi & Co., Ltd. Drug Profiles - A-836339 - AX-007 - BAM-822 - CR-701 - GERP-001 - LASSBio-873 - Recombinant Protein to Activate IL-4 and IL-10 Receptors for Osteoarthritis and CNS - Small Molecule to Antagonize P2X3 Receptor for Central Nervous System Disorders - Small Molecules to Inhibit FLT3 for Hyperalgesia and Neuropathic Pain For more information visit http://www.researchandmarkets.com/research/c7...peralgesia
ABBV: 69.23 (+1.26)
Pruritus Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 07, 1:00PM CDT
The report "Pruritus - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Pruritus. Pruritus is a common symptom, rather than a specific disease entity, that occurs in a diverse range of skin diseases and may appear as a prominent feature of extracutaneous disorders such as systemic, neurologic, and psychiatric diseases. The incidence of pruritus increases with age and is one of the most common complaints in the elderly patient population. Most often dry skin, otherwise known as xerosis is the commonest cause in these patients. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/pruritus-pip...eport.html .
GSK: 42.45 (+0.65)
International Fenofibrate Market Status & Forecast Report 2015-2020
PRWeb - Tue Apr 07, 7:31AM CDT
The 2015 Deep Market Research Report on Global Fenofibrate Industry is a professional and in-depth study on the current state of the global Fenofibrate Market with a focus on the Chinese situation.
Sezary Syndrome Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k76vbh/sezary_syndrome) has announced the addition of the "Sezary Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. Sezary Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Sezary Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sezary Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sezary Syndrome. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Sezary Syndrome Therapeutics Clinical Trials - Eisai Co., Ltd. - Merck & Co., Inc. - Shionogi & Co., Ltd. - Kirin Holdings Company, Limited - OncoSec Medical Inc. - Janssen Global Services, LLC - Emergent BioSolutions Inc. - arGEN-X BV - Angimmune LLC For more information visit http://www.researchandmarkets.com/research/k7...y_syndrome
EBS: 33.85 (+1.10), MRK: 57.95 (+0.57), ONCS: 5.75 (-0.06)
Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation
PR Newswire - Mon Mar 30, 1:00AM CDT
Naldemedine, an investigational peripherally acting mu-opioid receptor antagonist (PAMORA) under development by Shionogi & Co., Ltd., met its primary and secondary endpoints in a phase III study (COMPOSE I) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain receiving opioid therapy. Study results showed that naldemedine (0.2 mg tablet given once daily) statistically significantly improved the frequency of spontaneous bowel movement (SBM) compared with placebo over 12 weeks. Naldemedine was generally well-tolerated with the most commonly reported side effects being gastrointestinal disorders. This is the first phase III data generated from the COMPOSE program.
Cardiac Marker Diagnostic Testing Markets 2015
M2 - Mon Feb 16, 5:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/n3jhj5/cardiac_marker) has announced the addition of the "Cardiac Marker Diagnostic Testing Markets" report to their offering. Cardiac marker diagnostic testing measures the concentration of certain proteins, i.e., biomarkers, which indicate the presence or severity of cardiovascular disease (CVD). Among the most prevalent CVDs are sudden cardiac arrest (SCA), acute myocardial infarction (AMI), congestive heart failure (CHF) and atherosclerosis. Every year, an estimated 17 million people worldwide die from a CVD. This report describes the specific market segment of the in vitro diagnostics (IVD) market devoted to cardiac marker testing, including size; growth; industry trends; product development and investment; and clinical measurement devices, reagents and supplies. Highly-attractive cardiac marker areas of growth covered in this review include: the cardiac rapid assay market, troponins, Creatine kinase-myocardial band (CK-MB) and brain natriuretic peptide (BNP) testing. Also examined are heart failure, myoglobin, homocysteine (Hcy), C-reactive protein (CRP), pulmonary embolism (PE) (D-dimer test), low-density and high-density lipoproteins (LDL and HDL), stroke, cardiac enzymes, albumin, cardiac markers used in clinical decisions, cardiac markers in renal failure, cardiac panels and point of care (POC) cardiac markers. This study also provides a thorough analysis of the companies known to be marketing, manufacturing or developing cardiac marker products in the U.S. and worldwide, as well as detailed tables, charts and figures covering the U.S., Europe and Asia markets. Key Topics Covered: 1. Overview 2. The Basics of Biomarkers 3. Cardiac Marker Testing Markets: Market Segment Analysis: Size, Growth and Share 4. Cardiovascular Disease Markers 5. Cardiac Marker Testing Development Issues 6. Business Trends in the Industry 7. Important Technology Trends 8. Company Profiles - Abbott Laboratories and SWOT Analysis - Alere and SWOT Analysis - Beckman Coulter (now part of Danaher) - Biosite, Inc. (now a brand of Alere) - bioM?rieux - CardioGenics - Chek Diagnostics - diaDexus and SWOT Analysis - Health-Chem Diagnostics (HCD) - LifeSign, LLC - Ortho-Clinical Diagnostics, Inc. and SWOT Analysis - PTS Diagnostics - PreMD, Inc. - Radiometer Medical - Randox Laboratories Ltd. - Response Biomedical - Roche Diagnostics - Sanyo Chemical Industries Ltd. - Shionogi & Co., Ltd. - Siemens Healthcare Diagnostics - Sierra Resources International - Spectral Diagnostics, Inc. For more information visit http://www.researchandmarkets.com/research/n3...iac_marker
ABT: 49.93 (+0.74), DHR: 86.65 (+0.91)
Pruritus - Pipeline Review, H2 2014
M2 - Fri Dec 19, 4:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/m2s47z/pruritus) has announced the addition of the "Pruritus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pruritus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pruritus and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pruritus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amorepacific - Cara Therapeutics - Conrig Pharma - Creabilis - ELORAC - FAES Farma - GlaxoSmithKline - Hydra Biosciences - Johnson & Johnson - LEO Pharma - Merck & Co - NeRRe Therapeutics - Nippon Shinyaku - RDD Pharma - Santen Pharmaceutical - Shionogi & Co - Toray Industries - Trevi Therapeutics - Vanda Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/m2s47z/pruritus
JNJ: 99.53 (+1.13), VNDA: 12.41 (+0.33), MRK: 57.95 (+0.57), GSK: 42.45 (+0.65)
Osteosarcoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/kjklc9/osteosarcoma) has announced the addition of the "Osteosarcoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteosarcoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Osteosarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Oncolytics Biotech Inc. - Med Discovery SA - Aileron Therapeutics, Inc. - Merrimack Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Sutro Biopharma, Inc. - Eleison Pharmaceuticals, Inc. - Apoplogic Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/kj...teosarcoma
MACK: 12.08 (+0.43), ONCY: 0.58 (+0.03), BLCM: 19.58 (+0.74), GSK: 42.45 (+0.65)
Ewing Sarcoma - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/l4jf65/ewing_sarcoma) has announced the addition of the "Ewing Sarcoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ewing Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ewing Sarcoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shionogi & Co., Ltd. - Amgen Inc. - AstraZeneca PLC - Daiichi Sankyo Company, Limited - Sigma-Tau S.p.A. - Oncolytics Biotech Inc. - Merrimack Pharmaceuticals, Inc. - Pharma Mar, S.A. - EntreChem, S.L. For more information visit http://www.researchandmarkets.com/research/l4...ing_sarcom
MACK: 12.08 (+0.43), ONCY: 0.58 (+0.03), AZN: 66.45 (+1.90), AMGN: 154.10 (+2.79)
Allergic Rhinitis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5vk6r/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 3M Drug Delivery Systems - ALK-Abello - Allergopharma Joachim Ganzer - AnaptysBio - Axikin Pharmaceuticals - BioTech - Celsus Therapeutics - ELORAC - Fountain Biopharma - GlaxoSmithKline - GlycoMar Limited - Hisamitsu Pharmaceutical - Johnson & Johnson - KAEL-GemVax - Laboratorios LETI - Ligand Pharmaceuticals - Mitsubishi Tanabe Pharma Corporation - Nektar Therapeutics - NeoPharm - Novartis - Oxagen Limited - Panmira - Protectimmun - Revance Therapeutics - Rottapharm - Shionogi & Co - Stallergenes - Sumitomo Dainippon Pharma - Trimel BioPharma - VentiRx For more information visit http://www.researchandmarkets.com/research/w5...c_rhinitis
JNJ: 99.53 (+1.13), RVNC: 30.96 (+1.15), CLTX: 0.49 (-0.02), GSK: 42.45 (+0.65), NKTR: 11.40 (+0.22), NVS: 103.22 (+3.20)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.67 (+0.04), IMGN: 14.44 (+0.25), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), ONTX: 2.51 (-0.09), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), OXGN: 1.39 (+0.07), XLRN: 30.03 (+0.20), KPTI: 25.57 (+0.24), NVS: 103.22 (+3.20)
Shionogi Inc. Enlists BuzzeoPDMA, a Cegedim Company to Support their Sample Management Compliance Programs
Business Wire - Thu Sep 04, 12:00PM CDT
BuzzeoPDMA, A Cegedim Company, today announced that Shionogi Inc. has selected BuzzeoPDMA's sample management services to help the company maintain compliance with the FDA's PDMA regulations. Shionogi Inc., the U.S.-based subsidiary of Shionogi & Co., Ltd., a leading Japanese pharmaceutical company, focuses in the therapeutic areas of pain, women's health and cardiovascular disease.
Research and Markets: Global Postmenopausal Vaginal Atrophy Drugs Market 2014-2018 with Actavis, Novo Nordisk, Pfizer & Shionogi & Co. Dominating
Business Wire - Tue Jul 15, 8:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbvk9b/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering.
Global Postmenopausal Vaginal Atrophy Drugs Market 2014-2018 with Actavis, Novo Nordisk, Pfizer & Shionogi & Co. Dominating
M2 - Tue Jul 15, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mstbv/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering. The Global PVA Drugs market can be divided into two segments: Topical Estrogen and Systemic Estrogen. To calculate the market size, the report considers the revenue generated from the sales of various drugs (creams, tablets, and rings) used in the treatment of PVA. Vaginal atrophy is defined as decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after the menopause. Up to 40 percent of postmenopausal women have symptoms of atrophic vaginitis. In PVA there are symptoms of redness, burning, itching, dryness, irritation, and dyspareunia. HRT, estrogen creams, and other topical preparations are used in the treatment of PVA. The report, the Global PVA Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PVA Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actavis plc - Novo Nordisk A/S - Pfizer Inc. - Shionogi & Co. Ltd. Other Prominent Vendors - ANI Pharmaceuticals Inc. - Bionovo Inc. - EndoCeutics Inc. - QuatRx Pharmaceutical Co. - PeP-Tonic Medical AB - Teva Pharmaceutical Industries Ltd. - Therapeutics MD Inc. - Upsher-Smith Laboratories Inc. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Competitive Analysis of Marketed Products - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Types - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/5m..._pva_drugs
NVO: 57.68 (+2.91), ANIP: 62.22 (+1.36), PFE: 34.36 (+0.50), TEVA: 61.38 (-0.75)
